This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Mithra Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Mithra Pharmaceuticals's earnings have been declining at an average annual rate of -24.2%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 7.8% per year.
Key information
-24.18%
Earnings growth rate
-17.24%
EPS growth rate
Pharmaceuticals Industry Growth
5.95%
Revenue growth rate
-7.83%
Return on equity
-258.07%
Net Margin
-426.03%
Last Earnings Update
30 Jun 2022
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Mithra Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:MITP.F Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Jun 22
22
-93
16
76
31 Mar 22
22
-105
15
81
31 Dec 21
23
-117
14
85
30 Sep 21
21
-115
15
86
30 Jun 21
19
-113
16
87
31 Mar 21
14
-103
17
83
31 Dec 20
9
-92
17
78
30 Sep 20
44
-31
17
71
30 Jun 20
79
29
16
64
31 Mar 20
88
1
16
61
31 Dec 19
97
-27
16
57
30 Sep 19
84
-54
15
47
30 Jun 19
71
-82
14
37
31 Mar 19
64
-55
12
36
31 Dec 18
58
-28
11
36
30 Sep 18
46
-41
10
39
30 Jun 18
33
-53
10
42
31 Mar 18
33
-46
10
45
31 Dec 17
32
-38
10
48
30 Sep 17
26
-37
12
46
30 Jun 17
20
-36
13
43
31 Mar 17
21
-36
14
39
31 Dec 16
22
-35
16
34
30 Sep 16
21
-29
17
29
30 Jun 16
20
-23
19
24
31 Mar 16
20
-16
17
17
31 Dec 15
20
-10
15
9
Quality Earnings: MITP.F is currently unprofitable.
Growing Profit Margin: MITP.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MITP.F is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.
Accelerating Growth: Unable to compare MITP.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MITP.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: MITP.F has a negative Return on Equity (-258.07%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2022/12/05 13:59
End of Day Share Price
2022/09/07 00:00
Earnings
2022/06/30
Annual Earnings
2021/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mithra Pharmaceuticals SA is covered by 2 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.